Episode 4: Adverse-Risk Acute Myeloid Leukemia Episode 4: Adverse-Risk Acute Myeloid Leukemia
Drs Gail Roboz and Alexander Perl discuss adverse-risk acute myeloid leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Similar Survival, Less Toxicity With Decitabine vs Chemo in AML Similar Survival, Less Toxicity With Decitabine vs Chemo in AML
For patients with acute myeloid leukemia, treatment with decitabine prior to stem cell transplantation had similar overall survival and much less toxicity compared with intensive chemotherapy.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 12, 2022 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news
Division of Hematologic Malignancies 1 (DHM1)
regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologic Licensing Applications (BLAs) for Acute Leukemia and Myelodysplasia and Chronic Myeloid Leukemia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 10, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
New IMBRUVICA ® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Updated data from the FD cohort with three years of follow-up shows that I+V continues to demonstrate deep and durable responses and clinically meaningful progression-free survival (PFS) and overall survival (OS) in the first-line tre...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatmentUpdated data from phase III CLL14 study of Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1]Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was main...
Source: Roche Investor Update - June 10, 2022 Category: Pharmaceuticals Source Type: news
Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatmentUpdated data from phase III CLL14 study of Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1]Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was main...
Source: Roche Media News - June 10, 2022 Category: Pharmaceuticals Source Type: news
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Phase 3 SHINE Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
This study is one of the largest clinical trials ever conducted in first-line MCL and the first for a Bruton’s tyrosine kinase inhibitor (BTKi).[1] The data are being presented in an oral session and featured in a press briefing during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, and were published in The New England Journal of Medicine today. The data will also be presented as an oral presentation at the 2022 European Hematology Association (EHA) Annual Congress. MCL is a type of aggressive, rare non-Hodgkin lymphoma (NHL) that is incurable and difficult to treat.[2] It commonly affects people o...
Source: Johnson and Johnson - June 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
Recently,NBC News ’ Todaydid aprofile on one of the first pediatric patients in the world to receive a CAR-T cell therapy for the treatment of acute lymphoblastic leukemia (ALL). In April 2012, the patient was able to enroll in a pediatric phase I clinical trial to receive the CAR-T cell therapy,CTL019 or tisagenlecleucel.During the process, the patient ’s T-cells were separated from the bloodstream and genetically engineered to express a chimeric antigen receptor (CAR) — an artificial receptor that allows T-cells to recognize cancerous cells. Once returned to the body, the re-engineered cells enabled the patient’s...
Source: The Catalyst - May 25, 2022 Category: Pharmaceuticals Authors: Matthew Norawong Tags: Cancer Immunotherapy Source Type: news
Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Tibsovo is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia
FDA approval based on data from the global, Phase 3 AGILE trial that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 25, 2022 Category: Drugs & Pharmacology Source Type: news
Episode 3: Intermediate-Risk Acute Myeloid Leukemia Episode 3: Intermediate-Risk Acute Myeloid Leukemia
Drs Gail Roboz and Pinkal Desai discuss intermediate-risk acute myeloid leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development
Spring House, Pa., May 5, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the Measurable residual disease Partnership and Alliance in Acute myeloid leukemia Clinical Treatment (MPAACT), an industry-led research alliance founded in 2018 between Janssen Research & Development, LLC, Genentech (a member of the Roche Group), Novartis, and Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, and recently expanded with additional members Amgen, AbbVie, and Kronos Bio, is advancing efforts to establish measurable residual disease (MRD) as a surrogate endpoint for overall ...
Source: Johnson and Johnson - May 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS
(MedPage Today) -- Eprenetapopt combined with azacitidine as maintenance therapy after hematopoietic cell transplantation (HCT) improved outcomes for patients with TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 25, 2022 Category: Hematology Source Type: news
